research reports and media, page-618

Hi Ceviche,
this is from 51's March 8th 2019 research notes (when they went to Bene in Germany to visit the facility) and take directly with Bene.

"The exclusivity agreement between Paradigm and bene is updated each year, or when Paradigm in-license new patents (such as the recent MPS indication). With Paradigm holding patents around the use of PPS to treat various indications, it would be pointless for bene to supply PPS to a competitor - as the competitor could not sell or commercialise a product without violating Paradigm’s patents. Therefore, it's better to work together in a mutually beneficial partnership".

Hope that helps
cheers
Greg